Hypogonadism in opioid using males in an inner-city cohort: A cross-sectional study

Leen Wehbeh, MD; Adrian S. Dobs, MD, MHS; Todd T. Brown, MD, PhD

doi:10.5055/jom.2021.0624

Authors

Leen Wehbeh, MD
Adrian S. Dobs, MD, MHS
Todd T. Brown, MD, PhD

DOI:

https://doi.org/10.5055/jom.2021.0624

Keywords:

heroin, hypogonadism, methadone, opioid, testosterone

Abstract

Objectives: The link between male hypogonadism and opioids is well-established, but whether there is a difference in the frequency of hypogonadism between heroin and methadone for treatment of opioid use disorder (OUD) has not been determined.

Design: Cross-sectional.

Setting, patients, and participants: Male drug users and nonusers matched for socioeconomic status between 18 and 65 years, recruited in Baltimore as part of the study of HIV, injection drug use, nutrition, and endocrinology (SHINE).

Methods: Hypogonadism was defined as low free testosterone <50 pg/mL. Participants were categorized into three groups based on opioid use: (1) NONE, (2) methadone use as treatment of OUD (METHADONE), and (3) Heroin use (HEROIN). This third group was further divided to mild (MH), and heavy (HH) heroin use. We used multiple logistic regression to examine the association between hypogonadism and different groups.

Results: The cohort consisted of 189 men, 94 percent black, average age 43 years, with high HIV (56 percent) and HCV (38 percent) prevalence. 24 percent had hypogonadism. Compared to NONE, there were higher odds of hypogonadism in METHADONE (aOR 3.46; 95 percent CI [1.34,8.93]; p = 0.01) but not in HEROIN. After dividing HEROIN into MH and HH, there were higher odds of hypogonadism in HH compared to NONE (aOR 3.27; 95 percent CI [1.12,9.53]; p = 0.03) but not in MH.

Conclusions: Methadone used for treatment of OUD was associated with male hypogonadism similar to heavy heroin use. Targeted hypogonadism screening and treatment may be warranted in this population to reduce its health consequences such as sexual dysfunction, osteoporosis, and abdominal adiposity.

Author Biographies

Leen Wehbeh, MD

Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Adrian S. Dobs, MD, MHS

Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Todd T. Brown, MD, PhD

Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland

References

Betes M, Brennan T: Abusive prescribing of controlled substances—A pharmacy view. N Engl J Med. 2013; 369(11): 989-991. DOI: 10.1056/NEJMp1308222.

National Center for Injury Prevention and Control: CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2016 version. CDC. Available at https://www.cdc.gov/drugoverdose/media/. Accessed December 5, 2019.

Cicero TJ, Kasper ZA, Ellis MS: Increased use of heroin as an initiating opioid of abuse: Further considerations and policy implications. Addict Behav. 2018; 87: 267-271. DOI: 10.1016/j.addbeh.2018.05.030.

Vuong C, Van Uum SHM, O’dell LE, et al.: The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010; 31(1): 98-132. DOI: 10.1210/er.2009-0009.

Hallinan R, Byrne A, Agho K, et al.: Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009; 32(2): 131-139. DOI: 10.1111/j.1365-2605.2007.00824.x.

Azizi F, Vagenakis AG, Longcope C, et al.: Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1974; 22(4): 467-472.

Rhodin A, Stridsberg M, Gordh T: Opioid endocrinopathy: A clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain. 2010; 26(5): 374-380. DOI: 10.1097/AJP.0b013e3181d1059d.

Rubinstein AL, Carpenter DM: Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. Clin J Pain. 2013; 29(10): 840-845.

Rubinstein A, Carpenter DM: Elucidating risk factors for androgen deficiency associated with daily opioid use *. Am J Med. 2014; 127: 1195-1201. DOI: 10.1016/j.amjmed.2014.07.015.

Wong D, Gray D, Simmonds M, et al.: Opioid analgesics suppress male gonadal function, but opioid use in men and women does not correlate with symptoms of sexual dysfunction. Pain Res Manag. 2011; 16(5): 311-316.

Bliesener N, Albrecht S, Schwager A, et al.: Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005; 90(1): 203-206. DOI: 10.1210/jc.2004-0929.

Duarte R V, Raphael JH, Labib M, et al.: Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. Pain Physician. 2013; 16: 9-14.

Abs R, Verhelst J, Maeyaert J, et al.: Endocrine Consequences of Long-Term Intrathecal Administration of Opioids. Vol 85. 2000. Availble at https://academic.oup.com/jcem/articleabstract/85/6/2215/2851790. Accessed March 7, 2019.

Daniell HW: Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008; 9(1): 28-36. DOI: 10.1016/j.jpain.2007.08.005.

Mattick R, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review): Summary of findings for the main comparison. Cochrane Libr Syst Rev. 2014; 2014(2): CD002207. DOI: 10.1002/14651858.CD002207.pub4.www.cochranelibrary.com.

Mendelson JH, Mello NK: Plasma testosterone levels during chronic heroin use and protracted abstinence. Pharmacologist. 1974; 16(2): 529-533.

Mendelson JH, Meyer RE, Ellingboe J, et al.: Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther. 1975; 195(2): 296-302.

Lu WJ, Bies R, Kamden LK, et al.: Methadone: a substrate and mechanism-based inhibitor of CYP19 (Aromatase). Drug Metab Dispos. 2010; 38(8): 1308-1313. DOI: 10.1124/dmd.110.032474.

Martin ME, Benassayag C, Amiel C, et al.: Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+patients. J Endocrinol Invest. 1992; 15(8): 597-603. DOI: 10.1007/BF03344932.

Bhasin S, Brito JP, Cunningham GR, et al.: Testosterone therapy in men with hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103(5): 1715-1744. DOI: 10.1210/jc.2018-00229.

Brown TT, Wisniewski AB, Dobs AS: Gonadal and adrenal abnormalities in drug users: Cause or consequence of drug use behavior and poor health outcomes. Am J Infect Dis. 2006; 2(3): 130-135.

Monroe AK, Dobs AS, Cofrancesco J, et al.: Testosterone and abnormal glucose metabolism in an inner-city cohort. J Mens Heal. 2012; 9(3): 10. DOI: 10.1016/j.jomh.2012.03.010.

Bawor M, Dennis BB, Samaan MC, et al.: Methadone induces testosterone suppression in patients with opioid addiction. Sci Rep. 2014; 4: 6189. DOI: 10.1038/srep06189.

Cicero TJ, Bell RD, Wiest WG, et al.: Function of the male sex organs in heroin and methadone use. NEJM. 1975; 222(17): 882-887.

Bawor M, Bami H, Dennis BB, et al.: Testosterone suppression in opioid users: A systematic review and meta-analysis. Drug Alcohol Depend. 2015; 149: 1-9. DOI: 10.1016/j.drugalcdep.2015.01.038.

Daniell HW: Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002; 3(5): 377-384. DOI: 10.1054/jpai.2002.126790.

Yee A, Loh HS, Danaee M, et al.: Plasma testosterone and sexual function in southeast asian men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2018; 15: 159-166. DOI: 10.1016/j.jsxm.2017.12.004.

Aloisi AM, Ceccarelli I, Carlucci M, et al.: Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol. 2011; 9: 26. DOI: 10.1186/1477-7827-9-26.

Daniell HW, Lentz R, Mazer NA: Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006; 7(3): 200-210. DOI: 10.1016/j.jpain.2005.10.009.

Blick G, Khera M, Bhattacharya RK, et al.: Testosterone replaement therapy outcomes among opioid users: The testim registry in the United States (TRiUS). Pain Med. 2012; 13: 688-698.

Khera M, Bhattacharya RK, Blick G, et al.: The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012; 15(1): 14-21. DOI: 10.3109/13685538.2011.606513.

Blick G, Khera M, Bhattacharya RK, et al.: Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: Results from the TRiUS registry. Postgrad Med. 2015; 125(2): 19-29. DOI: 10.3810/pgm.2013.03.2638.